GlassScriptPhysician profile
Aleksandr Gorbatsevich
NPI 1538161005
$2,627.98
in general payments reported to CMS, 2019-2025
19 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $99.83 · 2021: $482 · 2022: $537 · 2023: $676 · 2024: $343 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $386.78 | 2021-2025 | Kimyrsa, Orbactiv, Vabomere |
| Merck Sharp & Dohme LLC | $363.22 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $363.20 | 2021-2025 | Fetroja |
| Pfizer INC. | $341.65 | 2019-2025 | |
| Abbvie INC. | $296.10 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $255.21 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $223.34 | 2019-2025 | Eliquis, Camzyos |
| Fisher Scientific Company L.L.C. | $63.41 | 2023 | Procalcitonin |
| Gilead Sciences, INC. | $56.89 | 2023-2025 | Yeztugo |
| La Jolla Pharmaceutical Company | $51.13 | 2023-2025 | Xacduro, Xerava |
| Novartis Pharmaceuticals Corporation | $44.46 | 2021-2022 | |
| Genzyme Corporation | $36.17 | 2025 | |
| Bioxcel Therapeutics, INC. | $24.25 | 2023 | Igalmi |
| Allergan, INC. | $23.77 | 2019-2020 | |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $22.25 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2022 | |
| Mylan Specialty L.P. | $17.47 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $14.97 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Gorbatsevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.